Despite being declared a global emergency over 20 years ago, one and a half million people still die from TB each year.
TB is the leading cause of death worldwide by a contagious disease and more than 2 billion people are infected with the causative agent, Mycobacterium tuberculosis.The standard drug therapy for TB uses combinations of four drugs over 6 months. Antimicrobial drug resistance (AMR) is a growing problem, with TB accounting for one third of drug-resistant bacterial infections. The recommended treatment for multidrug-resistant TB lasts 18–24 months or more, and is wholly dependent on increasingly toxic combinations of drugs. New drug regimens are needed to maintain and improve TB treatment success, shortening the duration of therapy and targeting drug-resistant bacteria.
The Wellcome Trust Brighton and Sussex Centre for Global Health Research works together with UK, European and international partners in collaborative research projects and multidisciplinary industry-university consortia to discover new strategies to reduce the burden of TB disease. We place knowledge exchange and multilateral research training between high/middle and low-income countries at the centre of our research agenda.
Dr Simon Waddell's (BSc, PhD, FHEA) main research areas include tuberculosis drug discovery, mycobacterial pathogenesis and TB biomarkers.
Read more >